Tyra Biosciences (NASDAQ:TYRA) Reaches New 52-Week High at $22.05

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $22.05 and last traded at $21.83, with a volume of 42592 shares changing hands. The stock had previously closed at $20.78.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Finally, Oppenheimer restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd.

Tyra Biosciences Stock Performance

The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -12.49 and a beta of 1.01. The company has a fifty day simple moving average of $18.18 and a two-hundred day simple moving average of $17.20.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, COO Daniel Bensen sold 3,502 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 15.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of TYRA. RA Capital Management L.P. increased its holdings in Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL increased its holdings in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares in the last quarter. Kynam Capital Management LP acquired a new position in Tyra Biosciences in the 4th quarter worth about $4,712,000. Vanguard Group Inc. grew its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after buying an additional 140,833 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $977,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.